Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.22 USD | -3.17% | +3.39% | -18.67% |
Apr. 09 | Transcript : Immunic, Inc. - Special Call | |
Mar. 21 | Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 98.14 | 316.8 | 251.2 | 62.1 | 67.72 | 109.9 | - | - |
Enterprise Value (EV) 1 | 98.14 | 189.3 | 176.3 | -54.27 | 21.04 | 76.78 | 165.4 | 256.7 |
P/E ratio | - | -5.44 x | -2.44 x | -0.37 x | -0.71 x | -1.23 x | -1.23 x | 1.12 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | 0.63 x |
EV / Revenue | - | - | - | - | - | - | - | 1.47 x |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 10,117 | 20,718 | 26,249 | 44,358 | 45,145 | 90,079 | - | - |
Reference price 2 | 9.700 | 15.29 | 9.570 | 1.400 | 1.500 | 1.220 | 1.220 | 1.220 |
Announcement Date | 3/16/20 | 2/26/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | 175 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -37.03 | -48.97 | -75.42 | -86.52 | -99.22 | -91.21 | -102.6 | 208 |
Operating Margin | - | - | - | - | - | - | - | 118.87% |
Earnings before Tax (EBT) 1 | - | -44.02 | -92.94 | -120.4 | -93.61 | -90.78 | -100.3 | 105.8 |
Net income 1 | - | -44.02 | -92.94 | -120.4 | -93.61 | -92.97 | -104.2 | 40.39 |
Net margin | - | - | - | - | - | - | - | 23.08% |
EPS 2 | - | -2.810 | -3.930 | -3.780 | -2.110 | -0.9880 | -0.9933 | 1.090 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/16/20 | 2/26/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -18.39 | -22.77 | -21.44 | -20.61 | -20.12 | -24.36 | -27.25 | -25.02 | -23.57 | -23.38 | -22.18 | -22.47 | -22.88 | -23.68 | -26.53 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -19.29 | -21.18 | -20.81 | -21.9 | -21.22 | -56.47 | -25.27 | -24 | -22.77 | -21.57 | -22.08 | -22.05 | -22.4 | -23.02 | -26.53 |
Net income 1 | -19.29 | -21.18 | -20.81 | -21.9 | -21.22 | -56.47 | -25.27 | -24 | -22.77 | -21.57 | -22.41 | -22.56 | -23.18 | -23.84 | -26.53 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.7600 | -0.6000 | -0.7400 | -0.7200 | -0.6900 | -1.620 | -0.5800 | -0.5400 | -0.5100 | -0.4800 | -0.2600 | -0.2360 | -0.2440 | -0.2440 | -0.2800 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/4/21 | 2/24/22 | 5/10/22 | 8/4/22 | 11/3/22 | 2/23/23 | 5/11/23 | 8/3/23 | 11/14/23 | 2/22/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | 55.5 | 147 |
Net Cash position 1 | - | 127 | 74.9 | 116 | 46.7 | 33.1 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | 0.07 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/16/20 | 2/26/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.67% | 110M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.41% | 22.15B | |
-17.37% | 21.02B | |
-8.91% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IMUX Stock
- Financials Immunic, Inc.